News | December 07, 2008

TandemHeart Played a Critical Role in Saving Teen’s Life

December 8, 2008 - There has been much discussion in recent weeks of the 14-year-old patient from Holtz Children’s Hospital in Miami living without a heart for more than 100 days, but what has not been reported are the facts behind the struggle as to how initially and immediately treat the young patient in post-transplant failure.

This patient was fairing so poorly that she could not be weaned from cardio pulmonary bypass. She faced great odds of expiring and was not in any condition to immediately endure a complicated surgical BiVAD insertion or another transplant, even if another organ was immediately available, said officials at CardiacAssist Inc., the makers of the TandemHeart. BIVAD.

Her surgeons chose to use the TandemHeart device as a bridge to the surgical BIVAD when it was not possible to wean from bypass immediately post-transplant. The TandemHeart provided the surgeons with a means to provide bi-ventricular support without the complex and invasive cannulation techniques required of surgical VAD placement. This enabled physicians to get the support necessary with minimal metabolic stress to either the patient or her heart. With the support of the TandemHeart, the physicians had the time necessary to make important decisions regarding the subsequent treatment for this particular patient after a few days.

“The TandemHeart played a critical role in early treatment of this patient’s transplant failure,” said Marco Ricci, M.D., assistant professor of surgery at Holtz Children’s Hospital. “While it is true that the next 100 days were accomplished thanks to the surgical BIVAD, we were really in a tough spot with few viable choices when we were unable to wean her from bypass. The TandemHeart was an important step in this case.”
The TandemHeart can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support. To date, the TandemHeart has been used nearly 1,500 times in 28 countries at 130 different facilities by 300 different physicians, the company said.

For more information: www.TandemHeart.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init